RECRUITING Phase 2 ClinicalTrials.gov

Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients

Sponsor: University of California, Davis • ClinicalTrials.gov ID: NCT02232191

Registry updated: 2026-08-18

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

Persons without a spleen are susceptible to potentially lethal infections from certain bacteria, with pneumococcus being the most prevalent. Vaccines are provided to help protect against these infections, though they do not so with certainty. Trauma patients who sustain an injury to their spleen currently have three treatment options available for the treating surgeon - nonoperative management, embolization, or removal of the spleen. The purpose of this study is to investigate the antibody response to pneumococcal vaccine in patients undergoing these modes of therapy.

Interventions

Pneumovax-23 (Biological)

Eligibility criteria

Inclusion Criteria: * Adult trauma patients (aged 18 to 65 years old) sustaining a splenic injury. Exclusion Criteria: * Ages less than 18 and greater than 65 * Initial planned nonoperative management patient who subsequently undergoes embolization or splenectomy will be withdrawn from the study.

Conditions

Asplenia

Locations

University of California, Davis Medical Center — Sacramento, California, United States

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment